Legal & General Group Plc Sells 4,264 Shares of argenex SE $ARGX

Legal & General Group Plc lessened its stake in shares of argenex SE (NASDAQ:ARGX) by 2.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 144,355 shares of the company’s stock after selling 4,264 shares during the period. Legal & General Group Plc owned 0.23% of argenex worth $121,395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after acquiring an additional 122 shares in the last quarter. NewEdge Advisors LLC grew its stake in argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth increased its holdings in shares of argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex Trading Up 2.2%

Shares of NASDAQ:ARGX opened at $838.49 on Friday. The stock’s fifty day simple moving average is $776.28 and its two-hundred day simple moving average is $815.12. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock has a market cap of $52.15 billion, a PE ratio of 37.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, sell-side analysts forecast that argenex SE will post 25.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Oppenheimer reduced their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Robert W. Baird upped their price objective on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Royal Bank Of Canada dropped their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, HC Wainwright upped their target price on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.